Published in Angiogenesis Weekly, March 14th, 2008
The MATRIX trial is a randomized, double-blind safety and efficacy research study in which Excellarate is topically administered once or twice over the course of the study, with a goal of complete ulcer closure at 12 weeks or earlier.
"The Excellarate topical gel, using...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Angiogenesis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.